LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biomarkers Evaluated for Severity of Diabetic Kidney Disease

By LabMedica International staff writers
Posted on 24 Aug 2020
Print article
Image: iCHROMA is an automatic or semiautomatic in-vitro diagnostic device that measures via cartridges the concentration of analytes, contained in blood, urine, or other samples, in quantitative or semi-quantitative ways (Photo courtesy of Boditech Med Inc).
Image: iCHROMA is an automatic or semiautomatic in-vitro diagnostic device that measures via cartridges the concentration of analytes, contained in blood, urine, or other samples, in quantitative or semi-quantitative ways (Photo courtesy of Boditech Med Inc).
Type 2 diabetic mellitus (T2DM) is a chronic metabolic disorder with multiple complications, including diabetic retinopathy, diabetic neuropathy, diabetic kidney disease (DKD) as well as cardiovascular diseases. T2DM is related to an exacerbated systematic inflammation.

Among all plasma inflammatory biomarkers, erythrocyte sedimentation rate (ESR) and high-sensitivity C-reactive protein (hsCRP) are the mostly commonly used laboratory tests for identifying systematic inflammation. Both ESR and hsCRP are important markers in various inflammation-related diseases.

A team of endocrinologists at Huashan Hospital (Shanghai, China) conducted a cross-sectional study in 1,210 patients with T2DM, among whom 265 had DKD. The severity of DKD was assessed by estimated-glomerular filtration rate (eGFR) and urinary albumin creatinine ratio (ACR). The relationship between ESR, hsCRP and DKD was analyzed by multivariate logistic analysis. The relationship between ESR and eGFR, ESR or ACR was analyzed by multivariate linear regression.

Fasting blood sample was collected to measure fasting plasma glucose (FBG), glycated hemoglobin (HbA1c), hsCRP, serum albumin (ALB), globulin (GLB), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL) and low-density lipoprotein cholesterol (LDL), serum creatinine (SCr), and ESR. ESR was measured using ESR-30 fully automatic dynamic analyzer (Xunda Medical Instrument Co., Ltd., Shanghai, China). FBG, TC, TG, HDL, LDL, ALB, total protein, SCr was quantified by Beckman AU5800 (Beckman Coulter Inc., Brea, CA, USA). HsCRP was detected by iCHROMA reader (Boditech Med Inc, Chungcheon-si, South Korea).

The scientists reported that ESR (23.0 mm/h [12.0 ~ 41.5] versus 12.0 mm/h [7.0 ~ 22.0], and hsCRP (3.60 mg/L [2.20 ~ 7.65] versus 2.90 mg/L [1.80 ~ 5.60],) values were significantly higher in patients with DKD than those without. Patients with higher ESR or hsCRP had lower eGFR and higher urinary albumin creatinine ratio (ACR). After adjusted for gender, age, hemoglobin, plasma proteins, HbA1c, lipid profiles, and the usage of renin-angiotensin system inhibitors, ESR but not hsCRP was independently associated with the rate and severity of DKD in patients with T2DM.

The authors concluded that their study underlined the role of inflammation in DKD. The study found that, both ESR and hsCRP correlated with DKD in T2DM, of which ESR was an independent risk factor for DKD and positively associated with severity of DKD. The study was published on July 13, 2020 in the journal BMC Endocrine Disorders



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.